logo
Twitter
Discord
Email
logo
Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

NASDAQ•AUPH
CEO: Mr. Peter S. Greenleaf M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2014-09-03
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Contact Information
118 Avenue , 14315, Suite 140, Edmonton, AB, T5L 4S6, Canada
250-744-2487
www.auriniapharma.com
Market Cap
$2.02B
P/E (TTM)
27.1
45.9
Dividend Yield
--
52W High
$16.20
52W Low
$6.55
52W Range
91%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$73.47M+8.41%
4-Quarter Trend

EPS

$0.24+140.00%
4-Quarter Trend

FCF

$44.38M+162.63%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Income Soars Nine months net income reached $76.41M USD, a massive increase from $4.32M USD in 2024, driven by strong sales growth.
Total Revenue Increased Total revenue for nine months was $205.94M USD, growing 17.5% from $175.27M USD, fueled by LUPKYNIS product sales.
Operating Cash Flow Strong Cash flow from operations was $89.99M USD for nine months, significantly up from $14.27M USD in the prior year period.
SG&A Expenses Reduced Nine months SG&A expense dropped $62.46M USD to $72.54M USD, reflecting benefits realized from 2024 strategic restructuring efforts.

Risk Factors

LUPKYNIS Patent Defense Facing multiple Paragraph IV ANDA challenges alleging invalidity of key 2037 Patents protecting LUPKYNIS exclusivity in the U.S. market.
Defamation Lawsuit Filed Company filed suit against Dr. Tidmarsh for defamation and injurious falsehood regarding voclosporin statements on November 2, 2025.
Increased R&D Spending Nine months R&D expense rose $8.93M USD to $21.61M USD, expected to increase further for continued development activities ahead.
Potential Financing Needs Future funding needs depend on LUPKYNIS success; company may raise additional capital via equity or debt financings if necessary.

Outlook

Aritinercept Clinical Progress Announced positive Phase 1 results for aritinercept; plans clinical studies in two autoimmune diseases by the end of 2025.
Realizing Restructuring Benefits Restructuring activities substantially completed in H1 2025; expects SG&A expense to remain lower compared to 2024 results.
Share Repurchase Activity Board approved $150M increase to Share Repurchase Plan; repurchased $98.16M USD worth of common shares year to date.
Continued IP Enforcement Company intends to vigorously enforce intellectual property rights related to LUPKYNIS against generic competitors moving forward.

Peer Comparison

Revenue (TTM)

Novavax, Inc.NVAX
$1.06B
+20.3%
Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
BioCryst Pharmaceuticals, Inc.BCRX
$599.82M
+45.4%

Gross Margin (Latest Quarter)

BioCryst Pharmaceuticals, Inc.BCRX
98.6%
+1.4 pp
Syndax Pharmaceuticals, Inc.SNDX
95.4%
-4.6 pp
Arcus Biosciences, Inc.RCUS
92.3%
-7.7 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EWTX$2.41B-15.8-30.6%0.7%
RCUS$2.17B-6.1-69.8%10.1%
AUPH$2.02B27.121.8%14.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+7.1%
Steady Growth
4Q Net Income CAGR
+180.5%
Profitability Improved
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $73.47M+8.4%
    |
    EPS: $0.24+140.0%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 31, 2025|
    Revenue: $70.01M+22.4%
    |
    EPS: $0.15+2900.0%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $62.47M+24.2%
    |
    EPS: $0.17-327.9%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $235.13M+34.0%
    |
    EPS: $0.04+107.4%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $67.77M+24.3%
    |
    EPS: $0.10-206.3%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $57.19M+37.8%
    |
    EPS: $0.01-106.2%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $50.30M+46.2%
    |
    EPS: $-0.07-58.6%
    Beat

  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 29, 2024|
    Revenue: $175.51M+31.0%
    |
    EPS: $-0.54+28.9%
    Miss